Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.
Official title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Participants With Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
252
Start Date
2026-07
Completion Date
2027-07
Last Updated
2026-07-08
Healthy Volunteers
No
Conditions
Interventions
HRS-4729 Injection
HRS-4729 Injection; Dose 1
HRS-4729 Injection
HRS-4729 Injection; Dose 2
HRS-4729 Injection
HRS-4729 Injection; Dose 3
HRS-4729 Injection;
HRS-4729 Injection; Dose 4
HRS-4729 Injection;
HRS-4729 Injection; Dose 5
HRS-4729 Injection;
HRS-4729 Injection; Dose 6
HRS-4729 Injection Placebo
HRS-4729 Injection Placebo
Locations (1)
Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China